Adenovirus infections - Pipeline Insight, 2021

Adenovirus infections - Pipeline Insight, 2021

  • May 2021 •
  • 60 pages •
  • Report ID: 6068384 •
  • Format: PDF
“Adenovirus infections – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenovirus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Adenovirus infections Understanding

Adenovirus infections: Overview
Adenoviruses are common viruses that cause a range of illness. They can cause cold-like symptoms, fever, sore throat, bronchitis, pneumonia, diarrhea, and pink eye (conjunctivitis). Most adenovirus infections are mild with few symptoms. While each child may experience symptoms differently, the most common include: Respiratory infections, Intestinal tract infections. Adenoviruses are contagious, which means an individual can pass them on to the other. The type of infection determines how it spreads. A Physical exam is generally carried for the diagnosis of Adenovirus infections. Certain blood tests may be done to evaluate the infection. These include: blood test, stool test, urine test and swab test. Children often get over the illness on their own within a few days. Some infections, like pink eye or pneumonia, can last for a week or more.

"Adenovirus infections - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenovirus infections pipeline landscape is provided which includes the disease overview and Adenovirus infections treatment guidelines. The assessment part of the report embraces, in depth Adenovirus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenovirus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Adenovirus infections R&D. The therapies under development are focused on novel approaches to treat/improve Adenovirus infections.

Adenovirus infections Emerging Drugs Chapters
This segment of the Adenovirus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adenovirus infections Emerging Drugs
• ALVR105 (Viralym-M): Allovir
Viralym-M is designed to play an important role in providing bridging immunity between conditioning and reconstitution of their immune systems. Viralym-M may substantially reduce or prevent virus-associated morbidity and mortality, and dramatically improve patient outcomes. ALVR105 is being studied in Phase II stage of development.

• Adenovirus-specific T cell therapy: Kuur Therapeutics
CytovirADV is naturally occurring VST cell products for the treatment of adenovirus infection reactivation. Kurr Therapeutics (formerly Cell Medica), in collaboration with the UCL Institute of Child Health and the Great Ormond Street Hospital for Children, is evaluating Phase I/II clinical trials for treatment of adenovirus infections.
Further product details are provided in the report……..

Adenovirus infections: Therapeutic Assessment
This segment of the report provides insights about the different Adenovirus infections drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Adenovirus infections
There are approx. 5+ key companies which are developing the therapies for Adenovirus infections. The companies which have their Adenovirus infections drug candidates in the most advanced stage, i.e. Phase II include, Allovir.
• Phases
This report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Adenovirus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adenovirus infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenovirus infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenovirus infections drugs.

Adenovirus infections Report Insights
• Adenovirus infections Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Adenovirus infections Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Adenovirus infections drugs?
• How many Adenovirus infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adenovirus infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenovirus infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adenovirus infections and their status?
• What are the key designations that have been granted to the emerging drugs?